EICHOR
● Completed
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
Condition: Prostatic Neoplasms · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 \[PCWG2\]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (27)
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, China | — |
| Peking University First Hospital | Beijing, China | — |
| Peking University People's Hospital | Beijing, China | — |
| Beijing Friendship Hospital | Beijing, China | — |
| Peking University Third Hospital | Beijing, China | — |
| Beijing Hospital | Beijing, China | — |
| Hunan Cancer hospital | Changsha, China | — |
| Sichuan Provincial Peoples Hospital | Chengdu, China | — |
| Chongqing University Cancer Hospital | Chongqing, China | — |
| Fujian Medical University Union Hospital | Fuzhou, China | — |
| Sun Yat-Sen Memorial Hospital Sun Yat-sen University | Guangzhou, China | — |
| Guangzhou First Municipal People's Hospital | Guangzhou, China | — |
+ 15 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04108208